Sirio Pharma Co., Ltd. Class A

Sirio Pharma Co., Ltd. Class A

SSZSE:300791
16.90
CNY
-0.46
(-2.65%)
0.00EPS
53.29P/E
5.67BMarket Cap
Apr 28Next Earn
Sirio Pharma Co., Ltd. Class A
SZSE:300791
(Shenzhen Stock Exchange)

Recent

price

16.90

P/E

ratio

53.29

div

yld

1.55%

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.43
3.06
3.41
19.34
3.45
5.84
7
6.38
6.8
7.79
8.24
11.75
13.87
13.95
13.14
Revenue per Share
0.2
0.24
0.27
1.32
3.08
0.46
0.89
0.58
0.85
0.76
0.7
0.92
1.07
0.45
0.35
Basic EPS, GAAP
-0.13
0.26
0.1
-1.26
-0.75
-0.48
-0.25
0.26
0.32
-0.6
0.5
-0.22
0.51
0.42
- -
Free Cash Flow per Basic Share
0.09
0.05
0.25
3.24
1.17
0.99
0.19
0.06
0.09
0.24
0.25
0.28
0.72
0.6
0.26
Dividend per Share
0.74
0.89
0.61
1.06
2.02
2.54
3.43
6.39
7.18
8.36
8.86
7.79
8.17
9.56
10.02
Book Value per Share
0.63
0.75
0.39
0.32
0.57
1.02
1.93
5.24
6.02
7.15
7.61
4.54
4.99
6.57
7.15
Tangible Book Value per Share
228
228
228
43
228
228
228
247
304
304
304
305
304
306
307
Basic Weighted Avg Shares
554
699
779
824
786
1,330
1,595
1,580
2,067
2,369
2,507
3,582
4,211
4,263
4,037
Sales/Revenue/Turnover
11.62
11.72
11.18
10.68
6.78
11.86
15.9
10.24
14.75
12.45
10.34
11.01
10.43
7.71
8.44
Operating Margin (%)
16
19
27
29
32
48
55
72
80
104
132
257
239
258
- -
Depreciation Expense
45
55
61
56
704
104
203
143
257
232
212
281
325
137
106
Net Income, GAAP
16.63
16.93
17.2
20.33
24.93
20.13
11.79
9.16
17.5
17.47
15.6
12.07
10.94
- -
- -
Effective Tax Rate (%)
8.19
7.81
7.89
6.82
89.51
7.84
12.74
9.02
12.45
9.79
8.47
7.85
7.72
3.2
2.63
Profit Margin (%)
-15
3
-128
-91
28
97
47
1,015
933
1,582
1,963
1,182
1,198
862
141
Working Capital
30
52
28
11
146
223
158
32
1
869
929
1,305
1,484
1,445
478
LT Debt
168
204
139
241
462
580
784
1,945
2,183
2,545
2,702
2,566
2,641
2,959
3,077
Total Equity
- -
18.56
19.14
13.49
94.19
10.27
18.18
8.41
12.15
8.45
6.33
6.53
7.07
- -
- -
Return on Invested Capital (%)
- -
20.55
22.64
16.25
105.5
12.54
19.83
9.52
12.13
8.63
7.04
10.32
11.07
- -
- -
Return on Capital (%)
- -
29.38
35.89
29.6
200.13
20.02
29.8
10.45
12.47
9.81
8.09
11.04
13.28
5.01
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
284
1,507
1,486
LT Borrowings
1,213
127
263
LT Finance Leases
313
213
215
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
308
309
308
Market Capitalization
6,251
4,945
5,674

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,011
2,316
2,532
Cash, Cash Equivalents & STI
669
782
990
Accounts Receivable, Net
688
776
773
Inventories
472
596
607
Total Current Liabilities
1,090
2,383
2,391
Payables & Accruals
- -
- -
- -
ST Debt
284
1,507
1,486
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
34.52%
6.54%
12.05%
Free Cash Flow
-100.2%
-193.73%
-16.74%
Net Income, GAAP
118.28%
-5.66%
-58%
Sales/Revenue/Turnover
19.65%
16.42%
1.23%
Total Cash Common Dividend
35.14%
68.18%
-16.66%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
952
1,039
1,058
1,163
4,211
2025
954
1,087
- -
972
4,263
2026
1,003
1,049
1,013
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
0.3
0.28
0.28
1.07
2025
0.23
0.3
- -
-0.4
0.45
2026
0.16
0.33
0.25
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.69
0.03
-0.01
0.72
2025
0.01
0.56
- -
0.02
0.6
2026
0.01
0.22
0.01
- -
- -
Business
Sirio Pharma Co., Ltd. serves as a prominent contract development and manufacturing organization for the global nutritional and health food sector. The company specializes in the creation and production of a diverse array of nutritional products, encompassing traditional and plant-based softgels, innovative nutraceutical gummies, probiotic formulations, tablets, powders, hard capsules, and functional liquids. Beyond manufacturing, it provides comprehensive, end-to-end solutions, including product research, development, custom packaging, logistics, and marketing assistance. Established in 1993, Sirio Pharma is headquartered in Shantou, China, with an expanding international presence, including manufacturing sites in the U.S. and Europe, supporting its "globally local" strategy. The company has demonstrated consistent growth, with its 2024 annual revenue reaching RMB 4.211 billion, reflecting a 17.56% year-over-year increase.